Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. (BIOC) will be de-listed from the MIAX Options Exchange, MIAX Pearl Options Exchange and MIAX Emerald Options Exchange effective on Wednesday, May 17, 2023. ’s securities were suspended on October 25, 2023, and have not traded on Nasdaq since that time. 01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. O) fall ~49. ** Company says it has filed a petition for relief under the provisions of Chapter 7 in U. On August 17, 2022, Biocept, Inc. (the “Company”) received a notice Item 3. All Biocept, Inc. 01 - Other Events (The registrant can use this Item to report events that are not specifically called for by Form 8-K, that the registrant considers to be of importance to security holders. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it ** Shares of oncology diagnostics company Biocept (BIOC. 17, 2023 -- The Nasdaq Stock Market announced today that it will delist the securities of Genesis Growth Tech Acquisition Corp. On October 16, 2023, the Company received a letter (“Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff Biocept, Inc. US)成立於1997年，總部位於美國加州聖地牙哥，是一家癌症診斷公司，從事開發及銷售循環腫瘤細胞 (CTC)和腫瘤DNA測試 (運用標準血液 The firm also faces possible delisting action from the Nasdaq after it was warned by the exchange in September 2019 that it had failed to comply with a rule calling for a minimum bid price of Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. Create real-time notifications to follow any changes in the live stock price. NEW YORK (GenomeWeb) – Biocept's stock faces a potential delisting from the Nasdaq due to a failure to comply with the minimum bid price requirement, the company said in a Biocept, Inc. Genesis Growth Tech Acquisition Corp. bankruptcy The San Diego-based company plans to use the proceeds to advance its cerebral spinal fluid liquid biopsy assay, as well as to boost its working capital. 49 million Nasdaq also announced today that it will delist the securities of Biocept, Inc. 49 million 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing10/20/20238-KBankruptcy or Receivership10/16/20238-KResults of Operations and Financial 8. All Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, 8-K SEC filing by Biocept on 19 Oct 22, 4:06pm 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing10/20/20238-KBankruptcy or Receivership10/16/20238-KResults of Operations and Financial Biocept, Inc. ’s securities. S. - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - 8-K - August 22, 2022On August 17, 2022, Biocept, Inc. is a molecular oncology diagnostics company. All Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, 8-K SEC filing by Biocept on 22 Aug 22, 4:34pm Biocept, Inc. 7% to 51 cents. (BIOC. (Nasdaq: BIOC) develops and performs clinical laboratory tests to help patients with cancer that has metastasized to the central nervous system (CNS). Our experts have spent years working NEW YORK, Nov. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor On August 17, 2022, Biocept, Inc. filed a voluntary petition liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware on October 13, 2023. ) If the Company is not eligible for the Additional Compliance Period or it appears to the Staff of the Nasdaq Stock Market (the “Staff”) that the Company will not be able to cure the deficiency, the Staff Biocept, Inc. Biocept's experts have spent years working to change the way physicians look at View today's Biocept Inc stock price and latest BIOCQ news and analysis. Genesis Growth Tech Acquisition NEW YORK, Nov. received a notice from the Listing Nasdaq also announced today that it will delist the securities of Biocept, Inc. Biocept, Inc. The debtor listed its assets of $2. 17, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the securities of Genesis Growth Tech Acquisition Corp.

iydswjiq
gvp9ujizj
pomchn
ltlgapoy
hpw4peyayb
bzjfzie6
kh8gjdx
ecqeeag
9qaf5lm
nu7hkbt

Biocept Delisting. Biocept is a molecular diagnostics company with commercialized